Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
Status:
Unknown status
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
There's high incidence of seborrhic dermatitis among patients suffering from Parkinson's
disease. Seborrhic dermatitis is caused by increased exertion of sebaceous glands. Previous
studies have shown an increase of sebum excretion rate in parkinsonian pateints. Other
studies demonstrated improvement in seborrhic dermatitis after anticholinergic treatment.
From these studies we concluded that there might be hyperactivity of the parasympathetic
system among PD patients, that cause increased exertion of sebum, therefore local injection
of botulinium toxin, which inhibitis acetyl choline realese, might improve the rash of
seborrhic dermatitis.
40 patients suffering from Parkinson disease or other parkinsonian disorders will participate
in this study.
Before treating the patients with botulinium toxin, we will measure the sebum exertion with
the sebumeter device and make clinical evaluation of the rash. We will also take a picture of
the rash.
Then Botulinium toxin (60- 100 units) will be locally injected to the rash area.
Two weeks after the injection the patients will be called and evaluated clinicly and by the
sebumeter. Then they will be checked again after 3 weeks, after a month and after two, three
and four month's.